US 7,612,173 B2
	Vaccine for prevention and treatment of HIV-infection
Helge Abrecht, Rixensart (Belgium); Martine Delchambre, Rixensart (Belgium); Martine Marchand, Rixensart (Belgium); Nathalie Louise Mathy, Rixensart (Belgium); Philippe Jean Gervais Ghislain Permanne, Rixensart (Belgium); and Gerald Hermann Voss, Rixensart (Belgium)
Assigned to GlaxoSmithKline Biologicals, s.a., Rixensart (Belgium)
Appl. No. 11/573,128 PCT Filed Aug. 03, 2005, PCT No. PCT/EP2005/008434 § 371(c)(1), (2), (4) Date Feb. 02, 2007, PCT Pub. No. WO2006/013106, PCT Pub. Date Feb. 09, 2006.
Claims priority of application No. 0417494.2 (GB), filed on Aug. 05, 2004.
Prior Publication US 2007/0243203 A1, Oct. 18, 2007
Int. Cl. C07K 14/00 (2006.01)

U.S. Cl. 530—350

26 Claims

1. A fusion polypeptide comprising a Nef polypeptide, a reverse transcriptase (RT) polypeptide, a p17 Gag polypeptide, and a p24 Gag polypeptide, wherein there is at least one HIV antigen between the p17 Gag polypeptide and the p24 Gag polypeptide.